# A Study to Evaluate the Safety and Tolerability and Explore the Efficacy of Zonisamide as add-on Therapy in Elderly Patients With Refractory Partial Seizures

> **NCT01546688** · PHASE4 · TERMINATED · sponsor: **Eisai Limited** · enrollment: 41 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** Zonisamide at targeted daily doses of 100-500 mg/day
- **DRUG:** Placebo administered to match targeted daily doses of 100-500 mg/day

## Key facts

- **NCT ID:** NCT01546688
- **Lead sponsor:** Eisai Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-11
- **Primary completion:** 2010-11
- **Final completion:** 2011-08
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2016-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01546688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01546688, "A Study to Evaluate the Safety and Tolerability and Explore the Efficacy of Zonisamide as add-on Therapy in Elderly Patients With Refractory Partial Seizures". Retrieved via MORVS 2026-10-18 from https://api.morvs.ai/clinical/NCT01546688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*